OpGen Q2 revenue $0.7M; cash only through Sep 2023; going concern doubt

CapForce Inc.

2023-Q2 EPS reported -$2.13 revenue$1,649,581

Q2 2023 revenue $0.7M vs $1.0M in Q2 2022 (prior year had one-time sale); H1 2023 revenue up 15% to $1.65M.
Operating expenses $5.9M in Q2 (down from $6.2M); H1 $11.9M vs $12.6M year-over-year.
Cash $3.2M at June 30, 2023; expects cash insufficient beyond Sep 2023; substantial doubt about going concern.
Business milestones: FIND collaboration extension, Fisher Healthcare distribution for Unyvero A50 in U.S., FDA De Novo submission for UTI panel under review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CapForce Inc. reported first half of 2023 results: revenue approximately $1.65 million.

Period: first half of 2023
Revenue: approximately $1.65 million
Result: reported results

Exact text from the filing

Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CapForce Inc. reported second quarter of 2023 results: revenue approximately $0.7 million.

Period: second quarter of 2023
Revenue: approximately $0.7 million
Result: reported results

Exact text from the filing

Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022

View on SEC.gov

Browse all earnings releases →

CapForce Inc. filing history →

Source: SEC EDGAR

accession 0001079973-23-001113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.